dc.contributor.author |
Lashkari, Harsha Prasada
|
|
dc.contributor.author |
Nash, Ruth
|
|
dc.contributor.author |
Albanese, Assunta
|
|
dc.contributor.author |
Okoye, Bruce
|
|
dc.contributor.author |
Millar, Robert P.
|
|
dc.contributor.author |
Pritchard-Jones, Kathy
|
|
dc.date.accessioned |
2014-05-12T07:10:04Z |
|
dc.date.available |
2014-05-12T07:10:04Z |
|
dc.date.issued |
2013 |
|
dc.description.abstract |
Sertoli–Leydig cell tumors are rare ovarian neoplasms. We report
two unusual cases with bilateral SLCTs suggesting evidence of
genetic predisposition and at high risk of recurrence. To reduce this
risk, we exploited the use of GnRH analog to lower gondadotropin
and potentially directly inhibit the tumors through expressed GnRH
receptors. We used it as maintenance antitumor therapy for 2 years after completion of chemotherapy, to cover the period of risk for
recurrence. Both patients remain in complete remission at >2 years
after completing leuprorelin therapy. Of note, both patients carry
DICER1 mutations, frequently found in pleuropulmonary blastoma
syndrome. |
en_US |
dc.description.librarian |
am2014 |
en_US |
dc.description.uri |
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017 |
en_US |
dc.identifier.citation |
Lashkari, HP, Nash, R, Albanese, A, Okoye, B, Millar, RP & Pritchard-Jones, K 2013, 'Treatment of high risk Sertoli-Leydig cell tumors of the ovary using a gonadotropin releasing hormone (GnRH) analog', Pediatric Blood and Cancer (Open Access), vol. 60, no. 6, pp. E16-E 18 |
en_US |
dc.identifier.issn |
1545-5009 (print) |
|
dc.identifier.issn |
1545-5017 (online) |
|
dc.identifier.other |
10.1002/pbc.24382 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/39756 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
Wiley-Blackwell |
en_US |
dc.rights |
© 2012 Wiley Periodicals, Inc. The definite version is available at : http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017 |
en_US |
dc.subject |
GnRH analog |
en_US |
dc.subject |
Leuprorelin |
en_US |
dc.subject |
Sertoli–Leydig cell tumor (SLCT) |
en_US |
dc.subject |
Sex cord stromal cell tumor |
en_US |
dc.title |
Treatment of high risk Sertoli-Leydig cell tumors of the ovary using a gonadotropin releasing hormone (GnRH) analog |
en_US |
dc.type |
Article |
en_US |